vk-2019
Small moleculeexperimental
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2019 (NCT03682055)
Timeline
Indications
Mechanism of action
- Epstein-Barr nuclear antigen 1INHIBITOR
EBNA1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06789159 | Phase 1 | Jan 31, 2025 | National Cancer Institute (NCI), The Wistar Institute, Thomas Jefferson University |
| NCT04925544 | Phase 2 | Aug 31, 2021 | National Institutes of Health (NIH), Stanford University |
| NCT03682055 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2019 | Cullinan Oncology, LLC, National Cancer Institute (NCI), Stanford University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 2019 |
| Stanford University | Academic/Hospital | 2 | 1 | 1 | 2019 |
| Cullinan Oncology, LLC | Academic/Hospital | 1 | 1 | 1 | 2019 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2021 |
| The Wistar Institute | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Thomas Jefferson University | Academic/Hospital | 1 | 1 | 1 | 2025 |
6 organizations
Page 1 / 1